66 filings
Page 2 of 4
8-K
em87bf7p d7f1sonpv
13 Dec 22
Magenta Therapeutics Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates
8:36am
8-K
m76025bk64f62 t8
3 Nov 22
Magenta Therapeutics Reports Third Quarter Financial Results
9:05am
8-K
axzwadx
17 Aug 22
Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors
8:12am
8-K
jhu40psa
4 Aug 22
Magenta Therapeutics Reports Second Quarter Financial Results
8:24am
8-K
uqlc931
30 Jun 22
Submission of Matters to a Vote of Security Holders
4:01pm
8-K
rn2bhzph0 vyq1v8lm
16 May 22
Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations from MGTA-117 Clinical Trial and Other Program Highlights
9:04am
8-K
tragnk8gsya
2 May 22
Departure of Directors or Certain Officers
4:07pm
8-K
v8p4cbksqgpf xd6s
14 Apr 22
Regulation FD Disclosure
8:34am
8-K
0nasm4p2lvb7a
8 Mar 22
Magenta Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Highlights
8:26am
8-K
aaybsavqj8cuk xwy
10 Jan 22
Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022
8:15am
8-K
gmeml6aod9g g90
4 Nov 21
Magenta Therapeutics Reports Third Quarter Financial Results
9:10am
8-K
yi8x1ebz wk
5 Aug 21
Magenta Therapeutics Reports Second Quarter Financial Results
8:12am
8-K
uzw3h94mv4smcui 2bki
27 Jul 21
Results of Operations and Financial Condition
4:55pm
8-K
hhq1vf0g0 9havjx
7 Jun 21
Departure of Directors or Certain Officers
8:09am
8-K
xf44gd8t3mu0wjre3d
27 May 21
Departure of Directors or Certain Officers
8:00am
8-K
vswq1egfcpvyzs1az
12 May 21
Magenta Therapeutics Announces $86.4 Million Common Stock Investment from Multiple Investors
4:31pm
8-K
nb2c1egm4dbzh6cvvni
6 May 21
Magenta Therapeutics Reports First Quarter Financial Results
8:11am
8-K
t7euw 1eokx5
3 Mar 21
Magenta Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Program Highlights
8:16am
8-K
bvpbjm ttgtz51i7je
11 Jan 21
Magenta Therapeutics Highlights Recent Progress and Expected Timing of 2021 Milestones, Including Four Ongoing and Planned Clinical Trials
8:16am
8-K
n30d xcjlahlodg1
23 Dec 20
Departure of Directors or Certain Officers
4:15pm